Absence of respiratory effects with ivabradine in patients with asthma
- 6 May 2008
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 66 (1), 96-101
- https://doi.org/10.1111/j.1365-2125.2008.03160.x
Abstract
Beta-Blockers are commonly prescribed for stable angina and are recommended as initial therapy. However, beta-blockers are contraindicated in patients with obstructive airway disease because of a risk of bronchoconstriction. Ivabradine is a specific heart rate-lowering agent that acts via I(f) pacemaker channels in the sinoatrial node with no beta-adrenoreceptor activity. Ivabradine has been recently approved for the treatment of stable angina. This study assessed the effects of repeated administration of ivabradine on lung function in patients with asthma. In this double-blind, placebo-controlled, crossover study, 20 subjects with asthma received either oral ivabradine 10 mg b.i.d. or placebo for 4.5 days. Forced expiratory volume in 1 s (FEV(1)) and peak expiratory flow rate (PEFR) were designated as the main outcome variable. Diary cards were used to monitor asthma symptoms on a five-point scale, rescue medication usage, and adverse events. There were no significant differences in mean variation of FEV(1) (ivabradine P = 0.664; placebo P = 0.652) or PEFR (ivabradine P = 0.153; placebo P = 0.356) from baseline following administration of ivabradine. There was also no significant difference in maximum percent variation in FEV(1) or PEF between treatment groups (P = 0.994; FEV(1) and P = 0.704; PEF). On a similar note, there was no significant difference in asthma symptoms or rescue medication usage reported between the two groups. Adverse events were generally mild-to-moderate in intensity and no cardiovascular or serious adverse events were recorded. This study confirms that ivabradine does not affect respiratory function or symptoms in patients with asthma and therefore represents a valuable therapeutic alternative to beta-blockers for treating patients with stable angina and asthma.This publication has 21 references indexed in Scilit:
- The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable AnginaEuropean Heart Journal, 2005
- Heart Rate Lowering by Specific and Selective If Current Inhibition with IvabradineDrugs, 2004
- A Single Intravenous Dose of Ivabradine, a Novel If Inhibitor, Lowers Heart Rate but Does Not Depress Left Ventricular Function in Patients with Left Ventricular DysfunctionCardiology, 2003
- An Unusual Death in an Asthmatic PatientAmerican Journal of Forensic Medicine & Pathology, 2003
- Antianginal and Antiischemic Effects of Ivabradine, an I f Inhibitor, in Stable AnginaCirculation, 2003
- Adverse effects of a single dose of (+)‐sotalol in patients with mild stable asthmaBritish Journal of Clinical Pharmacology, 1998
- Choosing the Most Appropriate Treatment for Stable AnginaDrug Safety, 1998
- Propranolol is contraindicated in asthmaBMJ, 1996
- Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cellsBritish Journal of Pharmacology, 1996
- Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane.BMJ, 1981